SCHEMBL24978136

SCHEMBL24978136

COCCOc1ccccc1C(CO)C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PPARG P37231 1/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
THRB P10828 1/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GLS O94925 1/20 0.38
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25500765 0.89 PPARG (0.46) KDM4EMAPTPPARGALDH1A1LMNA
SCHEMBL24977625 0.87 KDM4E (0.43) KDM4EPOLBMAPTNPSR1PPARG
Lithium Ion SCHEMBL29868648 0.84 PPARG (0.40) KDM4EPPARGTSHRL3MBTL1ALDH1A1
SCHEMBL24977253 0.82 GLS (0.38) KDM4EPOLBMAPTNPSR1PPARG
SCHEMBL28915627 0.77 PPARG (0.52) KDM4EPOLBMAPTNPSR1PPARG
SCHEMBL13082304 0.77 LMNA (0.39) KDM4EMAPTNPSR1PPARGL3MBTL1
SCHEMBL28569136 0.76 L3MBTL1 (0.50) KDM4EMAPTNPSR1TSHRL3MBTL1
SCHEMBL15910867 0.75 KMT2A (0.42) NPSR1TSHRALDH1A1THRBSMN1; SMN2
SCHEMBL23886940 0.74 CASP1 (0.46) ALDH1A1THRBKMT2A
SCHEMBL30370265 0.74 CASP1 (0.46) ALDH1A1THRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151016-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-05-18 US disclosed
US-20230151016-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-05-18 US disclosed
US-11566030-B2 Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-01-31 US disclosed
US-11566030-B2 Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-01-31 US disclosed
US-20220267337-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566030-B2 Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators PDK1, PDK2, PDK3 KDM4E 1382/4885POLB 1706/4885MAPT 3441/4885
US-20220267337-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS PDK1, PDK2, PKM KDM4E 1440/4885POLB 1306/4885MAPT 3365/4885
US-20230151016-A1 PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS PDK1, PDK2, PKM KDM4E 1440/4885POLB 1306/4885MAPT 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.